<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742985</url>
  </required_header>
  <id_info>
    <org_study_id>02-2020-048</org_study_id>
    <nct_id>NCT04742985</nct_id>
  </id_info>
  <brief_title>Effects of Green Tea Extracts on Gastric Mucosal Protection</brief_title>
  <official_title>Effects of Combined Extracts of Green Tea Seed (Saponins) and Green Tea Leaves (Epigallocatechin-3-gallate) on Gastric Mucosal Protection: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Yangsan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conduct a randomized, double-blind, placebo-controlled pilot study to&#xD;
      investigate the effects of a combined extract of green tea seed (saponins) and green tea&#xD;
      leaves (epigallocatechin-3-gallate) on gastric mucosal protection in adults with functional&#xD;
      dyspepsia for 8 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A previous study has indicated that combined extract of green tea seed (saponins) and green&#xD;
      tea leaves (epigallocatechin-3-gallate) may improve gastric mucosal status in rat with&#xD;
      alcohol-induced gastritis.Therefore, the investigators conduct a randomized, double-blind,&#xD;
      placebo-controlled pilot study to investigate the effects of a combined extract of green tea&#xD;
      seed (saponins) and green tea leaves (epigallocatechin-3-gallate) on gastric mucosal&#xD;
      protection in adults with functional dyspepsia for 8 weeks; the safety of the compound are&#xD;
      also evaluated. The Investigators examine C-reactive protein, IFN-γ, TNF-α, gastrin,&#xD;
      malondialdehyde, 8-hydroxy-2' -deoxyguanosine, and questionnaires (Gastrointestinal Symptom&#xD;
      Rating Scale, Nepean dyspepsia index-Korean version, Nepean dyspepsia index-Korean version&#xD;
      QOL questionnaire, Gastrointestinal symptom scale) at baseline and after 8 weeks of&#xD;
      intervention. Twenty four adults were administered either 320 mg of combined extracts of&#xD;
      green tea seed (saponins) and green tea leaves (epigallocatechin-3-gallate) or a placebo each&#xD;
      day for 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale (score)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Gastrointestinal Symptom Rating Scale - questionnaire evaluated at baseline and after 8 weeks. It ranges from the minimum of 0 to the maximum of 75. A higher score indicates a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>concentration of high-sensitivity C-reactive protein (mg/L)</measure>
    <time_frame>8 weeks</time_frame>
    <description>high-sensitivity C-reactive protein (mg/L) measured at baseline and after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of interferon-γ (pg/mL)</measure>
    <time_frame>8 weeks</time_frame>
    <description>interferon-γ (pg/mL) measured at baseline and after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of tumor necrosis factor-α (pg/mL)</measure>
    <time_frame>8 weeks</time_frame>
    <description>interferon-γ (pg/mL) measured at baseline and after 8 weeks measured at baseline and after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of gastrin (pg/mL)</measure>
    <time_frame>8 weeks</time_frame>
    <description>gastrin (pg/mL) measured at baseline and after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of malondialdehyde (mic·mol/L)</measure>
    <time_frame>8 weeks</time_frame>
    <description>malondialdehyde (mic·mol/L) measured at baseline and after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of 8-hydroxy-2' -deoxyguanosine (ng/100 mg of protein)</measure>
    <time_frame>8 weeks</time_frame>
    <description>8-hydroxy-2' -deoxyguanosine (ng/100 mg of protein) measured at baseline and after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nepean dyspepsia index-Korean version (score)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Nepean dyspepsia index-Korean version - questionnaire evaluated at baseline and after 8 weeks. It ranges from the minimum of 0 to the maximum of 195. A higher score indicates a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nepean dyspepsia index-Korean version QOL questionnaire (score)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Nepean dyspepsia index-Korean version QOL questionnaire evaluated at baseline and after 8 weeks. It ranges from the minimum of 0 to the maximum of 125. A higher score indicates a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal symptom scale (score)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Gastrointestinal symptom scale questionnaire evaluated at baseline and after 8 weeks. It ranges from the minimum of 0 to the maximum of 40. A higher score indicates a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Green tea combined extracts group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group takes Green tea combined extracts (62.5 mg) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Green tea combined extracts group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group takes Green tea combined extracts (125 mg) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group takes placebo for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Green tea combined extracts group</intervention_name>
    <description>Green tea combined extracts 320 mg/day (main compound 62,5 mg for A group, 125 mg for B group) during 8 weeks</description>
    <arm_group_label>Green tea combined extracts group A</arm_group_label>
    <arm_group_label>Green tea combined extracts group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo group</intervention_name>
    <description>Placebo 320 mg/day during 8 weeks</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The Rome IV criteria define dyspepsia as any combination of 4 symptoms: postprandial&#xD;
             fullness, early satiety, epigastric pain, and epigastric burning that are severe&#xD;
             enough to interfere with the usual activities and occur at least 3 days per week over&#xD;
             the last 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients complaining of severe gastrointestinal symptoms requiring immediate&#xD;
             medication&#xD;
&#xD;
          -  Those with a history of gastric acid hypersecretion such as Zollinger-Ellison Syndrome&#xD;
&#xD;
          -  Those who received Helicobacter pylori eradication therapy within 4 weeks&#xD;
&#xD;
          -  Those who have taken nonsteroidal anti-inflammatory drugs, steroid drugs or&#xD;
             antibiotics, aspirin or antithrombotic drugs, or gastric acid suppressants within 4&#xD;
             weeks&#xD;
&#xD;
          -  Those who have a history of upper gastrointestinal tract surgery, stenosis, bleeding,&#xD;
             esophageal dilatation, gastric mucosal resection, etc. within the past 1 year&#xD;
&#xD;
          -  Patients with gastric ulcer (active or healing), duodenal ulcer (active or healing),&#xD;
             reflux esophagitis (LA B or higher), or malignant tumors from gastroscopy performed&#xD;
             within the last 6 months&#xD;
&#xD;
          -  Abnormal liver or renal function (more than twice the normal upper limit of the&#xD;
             research institute)&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (&gt;160 mg/dL of fasting blood sugar)&#xD;
&#xD;
          -  History of fracture during the previous year&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt;160/100 mmHg)&#xD;
&#xD;
          -  Uncontrolled thyroid diseases.&#xD;
&#xD;
          -  History of serious cerebro-cardiovascular diseases or cancer such as angina or&#xD;
             myocardial infarction within 6 months&#xD;
&#xD;
          -  History of any central bone fracture within 1 year&#xD;
&#xD;
          -  History of medication for psychiatric diseases such as severe depression,&#xD;
             schizophrenia, drug intoxication.&#xD;
&#xD;
          -  Alcohol abuser&#xD;
&#xD;
          -  Allergic reaction to Ishige Okamurae&#xD;
&#xD;
          -  Those who participated in other drug clinical trials within 1 month from the screening&#xD;
             date.&#xD;
&#xD;
          -  Severe gastrointestinal symptoms such as heartburn and indigestion&#xD;
&#xD;
          -  Those who are pregnant, lactating, or plan to become pregnant during the clinical&#xD;
             trial&#xD;
&#xD;
          -  Those who are judged to be unsuitable by the PI for other reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Yeoup Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Yangsan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeungsangnam-do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Yangsan Hospital</investigator_affiliation>
    <investigator_full_name>Sang Yeoup Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

